HSIC
74
3
EMC
60
-4
COST
54
6
PEP
77
3
C
55
-6
QCOM
37
-5
AMG
66
-3
SIG
75
-7
PH
57
-2
TDC
65
2
TAP
35
4
HPE
49
7
BAX
35
-7
OMC
64
10
NTRS
54
-3
GOOG
50
4
LMT
75
3
AN
30
-2
UNH
32
2
AEE
78
2
HSIC
74
3
EMC
60
-4
COST
54
6
PEP
77
3
C
55
-6
QCOM
37
-5
AMG
66
-3
SIG
75
-7
PH
57
-2
TDC
65
2
TAP
35
4
HPE
49
7
BAX
35
-7
OMC
64
10
NTRS
54
-3
GOOG
50
4
LMT
75
3
AN
30
-2
UNH
32
2
AEE
78
2
Financhill
Back

Kymera Therapeutics, Inc. 10K Form

Buy
68

KYMR
Kymera Therapeutics, Inc.

Last Price:
$90.10
Seasonality Move:
-21.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $39.2M
Cash Flow: $-66.9M
Price / Cash Flow: 0
Annual Sales: $19.42
Price / Book: 4.16

Profitability

EPS (TTM): -3.67930
Net Income (TTM): $-311.4M
Gross Margin: $30.9M
Return on Equity: -30.41%
Return on Assets: -26.51%

Kymera Therapeutics, Inc. Earnings Forecast

Key Kymera Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 8 years for KYMR is 78.80%.
  • The Selling, General & Administrative Expenses for KYMR have been equal to 173.90% of Gross Profit Margin.
  • The Research & Development expenses have been 786.14% of Revenue.
  • The Net Earning history of KYMR is -794.04% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Kymera Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 10.47
Quick Ratio: 10.19

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Buy
68
Kymera Therapeutics, Inc. (KYMR) is a Buy

Is Kymera Therapeutics, Inc. a Buy or a Sell?